

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

Year Three of COVID-19: Harsh Truths, Brutal Realities, and Glimmers of Hope

Gregory A. Poland, MD, Meltiady Issa, MD, MBA, Karna Sundsted, MD

PII: S0025-6196(22)00613-9

DOI: https://doi.org/10.1016/j.mayocp.2022.10.022

Reference: JMCP 3985

To appear in: Mayo Clinic Proceedings

Received Date: 26 October 2022

Accepted Date: 26 October 2022

Please cite this article as: Poland GA, Issa M, Sundsted K, Year Three of COVID-19: Harsh Truths, Brutal Realities, and Glimmers of Hope, *Mayo Clinic Proceedings* (2022), doi: https://doi.org/10.1016/j.mayocp.2022.10.022.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Mayo Foundation for Medical Education and Research



Journal Pre-proof

Year Three of COVID-19: Harsh Truths, Brutal Realities, and Glimmers of Hope

Gregory A. Poland, MD; ^{1,2,} Meltiady Issa, MD, MBA; ³ Karna Sundsted, MD; ³

¹Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN, USA

²Division of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN,

USA

³Division of Hospital Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN,

USA

Keywords: COVID-19, SARS-CoV-2, vaccines, viral variant, immunity

Address correspondence to:

Gregory A. Poland, MD, Director, Mayo Clinic Vaccine Research Group, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905

Phone: (507) 284-4968; Fax: (507) 266-4716;

Email: Poland.gregory@mayo.edu

Abstract

SARS-CoV-2, the virus causing COVID-19, has now killed 1 out of every 303 Americans. While four vaccines are available in the US, and masks widely available, too few are fully immunized and most of the population has stopped wearing protective masks. The ongoing consequences of this include continued excess morbidity and mortality, the generation of immune-evading variants and sub-variants, and *in toto* are injurious and ultimately self-defeating. Herein we briefly update and review COVID-19 vaccines, waning immunity, and new variants.

Harsh Truths

SARS-CoV-2 is a novel virus with a rapidly changing and highly mutable genotype. The available data are highly kinetic and dynamic, occurring in an environment of uncertainty but with periodic yet repeated surge-related morbidity and mortality coupled with, and often driven by, distorted human behavior. The reality is that much of what we think we know about SARS-CoV-2 is likely wrong, outdated, tinged with false presuppositions, and often based on belief-dependent realism and tribalistic thinking. Instead, the best way of knowing truth for a scientific issue is the scientific method, albeit that can often be incompatible with what the public wants to believe.

Everything we understand thus far about SARS-CoV-2 is conditional upon time, variant, geography, type of host immunity, host factors and behavior, population structure, and levels of immunity at the macro and micro levels, community burden of transmission, and the interplay among the above. The story of this pandemic, when it is written, is going to be seen as highly dependent upon, and perturbed by, both human and viral behavior. We only get to influence the first factor (human behavior) though it obviously influences the second (viral behavior). Therefore, we will continue to see the evolution of viral variants - some of which have, are, and will continue to develop the ability to evade, in whole or in part, both vaccine-induced and illness-induced immunity, as well as prevention and treatment with antivirals and monoclonal antibodies.

The unfortunate and harsh truth about COVID-19 in the U.S. is that over a million COVID-19 deaths have occurred as of this writing. There have been 225,000 confirmed COVID deaths in the US thus far in 2022 alone, despite the widespread availability of safe and effective vaccines. One out of every 303 Americans is now dead of COVID-19, with a continuing toll currently of 300-400 deaths per day. We have had more deaths nationwide than deaths due to the 1918 US influenza pandemic. A major reason for this is that currently only 68% of Americans are fully vaccinated, and only 33% boosted. Less than 10% of eligible Americans have received the newer updated bivalent booster.

If we examine the data from other developed countries with the ability to accurately track vaccine uptake, the US has among the lowest percentage of the population that have received a booster dose, and therefore it is no surprise that we had more cumulative deaths per capita during the Omicron wave than any of these other countries. In fact, the US has had the highest death rate of any of 21 other high income countries. While it is unthinkable that this could be the case, we must accept that the data are the data. Globally, the WHO has estimated that approximately 15 million people have died due to COVID-19.

Brutal Realities of COVID-19 in the United States

An examination of the current average daily new COVID-19 cases reveals that the unvaccinated have about three times the rate of acquiring new cases compared to the fully vaccinated, in addition to a 6-fold higher risk of death. While death rates have fallen as of May 2022, case

rates soared to over 100,000 new cases in the US per day through the Spring and Summer of 2022 – and this is a likely a vast underestimate due to extensive home testing that never gets reported. Yet, consistent with belief-dependent realism, no amount of data has swayed vaccine-hesitant and rejecting individuals.

There are multiple distorting human factors impacting the ability to manage the pandemic, from individual and collective human behavior patterns to a false epistemology by which the public attempts to understand and manage the pandemic. Human behavior during the pandemic has included vaccine hesitancy and rejection, rejection of masks, political and economic conflicts of interest, lack of leadership, and the discovery of animal reservoirs such as the white tail deer and mink who have been infected by human activity. Additionally, we are dealing with pathological cultural narcissism (a "me" not "we" mentality), and the false presupposition of the democratization of expertise. Ultimately these factors are, and have been, injurious, self-defeating and self-destructive. Ultimately, and indicative of massive issues that will occur into the future, we have lost any collective transcendent reference points by which we make decisions and act for one another's and society's interest.

SARS-CoV-2 Variants and the Lies We Tell Ourselves

The spike protein projecting from the SARS-CoV-2 virus is composed of a number of parts, primarily the S2 and S1 domains and contained within the S1 or distal part of the spike protein is the receptor binding domain (RBD). The RBD binds to the human ACE2 receptor allowing the

virus to enter the cell and hijack host cellular machinery in order to manufacture massive numbers of viral progeny.³ If we examine the number and location of mutations in 3 SARS-CoV-2 Variants (wild type, Delta, and Omicron), one is struck by the significantly enhanced numbers of mutations from the original Wuhan ancestral strain to the Omicron variant. Not surprisingly, many of those mutations have accumulated in the RBD. As a result, as these types of variants arise, we begin to lose some level of effectiveness from illness-induced and vaccine-induced immunity as well as the efficacy of specific monoclonal antibodies as the virus mutates to evade immunity. The pattern of viral mutations often exactly matches the binding site between viral RBD and monoclonal antibody binding, accounting for loss of neutralizing activity.

Since December 2021, the predominant circulating variant in the US has been the Omicron variant. Importantly, this was completely unpredictable, as the expectation was that Delta subvariants would be next to arise. The Omicron variant was isolated in Botswana in November 2021 and then rapidly spread throughout South Africa and the rest of the world. Even though we have observed this type of pattern globally previously, it is important to note that if we go back to that early December 2021 timeframe, most of the world believed Omicron would not be a problem. Omicron subsequently became widely geographically dispersed. It is significantly more transmissible than Delta but fortunately seems to have somewhat lower virulence compared to Delta, likely because of its propensity for upper rather than lower airway infection, and some level of population immunity. Omicron demonstrated a larger genetic distance than any other variant of concern (VOC) from the ancestral strain, and is better able to escape illness and vaccine-induced immunity compared to other VOCs, as well as evasion of

the therapeutic effect of monoclonal antibodies. One consequence of this enhanced transmissibility was the significantly enhanced infection rate of children versus the other VOCs.

BA.2 - "Stealth" Omicron

Although we again heard that it would not be an important public health issue, BA.2, the "stealth" omicron, represented most new cases globally by April 2022. For example, the incidence in the Republic of South Africa went from about 22% of sequenced viruses to 86% between February 4th and 11th 2022, and BA.2 subsequently outcompeted Omicron globally. It is approximately 30% more transmissible than Omicron. There is evidence of increased virulence and immune evasion capability with reduced efficacy of sotrovimab and a requirement for double the dose of tixagevimab-cilgavimab as prophylaxis. Since May, the US and Europe have experienced yet another wave of COVID-19, this time due to Omicron subvariants – BA 2.12, BA 2.12.1., and BA 4/5. Currently, a variant under monitoring is the BA 2.75.2 subvariant which may further evade illness- and vaccine-induced immunity, as well as all monoclonal antibody's except bebtelovimab. More worrisome has been the rapid evolution and spread of additional Omicron subvariants including BA.5 variants (BQ.1, BQ.1.1, BF.7, BQ.X, XBB, BJ.1, other), BA.2 variants (BA.2.75.2, BS.1), BA.4 variants (BA.4.6), and others. Several of these arising variants may very well evade, in whole or in part, vaccine- and illness-induced immunity as well as monoclonal antibodies.

In addition to viral virulence, we must also be concerned with viral transmissibility. As an example, let us take a baseline community that has a steady 10,000 infections. Let us assume that each new case generates an average of 1.1 new cases, and that around 0.8% of new cases result in death. In one months time, approximately 129 deaths would be expected. However, what happens if the virus is 50% more lethal like Delta? The number of deaths would jump to nearly 200 in one month. Instead of changing lethality, what if we instead make the virus 50% more contagious like 0micron? Now, after a month, there are 978 deaths — or a 658% increase! That's what causes exponential spread. Human decision makers cannot deal, in a timely manner, with exponentiality. They always get it wrong — hence the astounding and continuing levels of COVID-19 morbidity and mortality.

Another way to think about exponentiality is by taking 2 scenarios, assuming 10 cycles of transmission in a naïve population, where we vary R_0 which is the basic reproductive rate of the virus – a measure of how many people, on average, an infected person would subsequently infect:

- Scenario A with Ro = 2.5: Leads to 9,536 infections
- Scenario B with Ro = 6: Leads to 60,466,176 infections

This important principal of exponentiality is what allowed us to predict that Omicron would lead to a worse surge and more deaths compared to Delta, which was counterintuitive to many decision makers. In fact, compared to the 2021 winter peak, Omicron cases rose 300%,

hospitalizations 115%, and deaths 59%. Worse, the newer Omicron subvariants demonstrate $R_{\rm O}$ values closer to 12, accounting for the significant surge in new cases in the US.

COVID-19 Vaccine - Efficacy and Effectiveness

When it comes to vaccine efficacy, there is a complex interplay between host characteristics, pathogen characteristics, vaccine type, time since vaccination and geography. Host characteristics include demographic differences, genetic factors, existing immunity, and comorbidities. Viral characteristics include the specific variant, inoculum size, and portal of entry.

What Is Vaccine Efficacy?

Vaccine efficacy (VE) can be viewed as a gradient of protection. Like virtually all our vaccines, SARS-CoV-2 vaccines are far better at blocking *disease* versus blocking *infection*. If we look at prevention of death, the mRNA vaccines were reported as 95% efficacious (against the Alpha variant), but if we look at asymptomatic infection and transmission, depending on the amount of time lapsed since last dose, it could be 0-40%. VE depends on multiple factors such as the underlying immune system health (innate, adaptive humoral, adaptive cellular) in the host, pre-existing immunity, predominant circulating variant, community burden of transmission, and genetic factors. Overall, for the population we can consider that there are 3 "enemies" to the development of immunity after vaccination: age, variant, and time.

With age comes immunosenescence and decreased vaccine immunogenicity, along with a growing number of medical comorbidities. In general, if we look at people who were immunized in their 20s to 40s, they develop an abundant antibody response. On the other hand, people immunized in their 60s to 80s with the same vaccine under the same conditions develop much lower level of antibodies. So, with age we generally become more susceptible to infection and develop less robust immune responses to vaccines – a condition known as immunosenescence.⁷

With new variants have come mutations and recombination events resulting in immune evasion and the decreased ability of neutralizing antibody to bind virus and block attachment to cell receptors. We see a similar trend when looking at the effect of VOC plus age. For example, if we measure neutralization of both the WA1/2020 strain and P1 variant, we find that not only neutralizing ability wanes with time, but at any one time point there is a difference (decrease) in the amount of measurable neutralizing antibodies by increasing age. In one study there was a measurable and highly significant 22-fold drop in neutralization of the Omicron variant by Pfizer vaccine-elicited immunity. So logically, even vaccinated individuals are going to become more susceptible to infection in a shorter period of time due to Omicron and Omicron subvariants circulating, and of course, this is exactly what has happened.

If we look at the first 3 approved vaccines in the US, and track the hazard ratio for becoming PCR positive (i.e. infected) after adjusting for age, race, ethnicity, sex, and comorbidities,

Janssen wanes the fastest, followed by Pfizer, followed by Moderna, the latter being most likely a dose effect.⁹ Thus, with increasing time, antibody levels and therefore protection does decrease. Vaccine effectiveness for infection over time also differs among the three vaccines. Over a six-month time period effectiveness against infection for adults in the U.S. wanes from about 89% to 58% with Moderna; from 87% to 43% with Pfizer; and from 86% to 13% with J&J.9 Effectiveness against death and severe disease however is relatively well-maintained, which reflects the gradient of protection previously discussed. This likely reflects the fact that prevention of disease tends to be more T-cell mediated while prevention of infection is B-cell mediated.¹⁰ Unfortunately, we do not have a suitable standardized method for routine measurement of cellular immune responses to vaccination for clinical use. Newer data on Pfizer vaccine effectiveness showed the same trend. 11 During an Omicron predominant time period, effectiveness in healthy 12-15-year-olds against ED/urgent care visits after 2 vaccine doses (14-149 days earlier) was 45%, with no measurable efficacy after 150 days. We see the same phenomena if we look at the same data for healthy 16–17-year-olds, but if they received 3 doses, vaccine effectiveness was boosted back up to 81%. Regardless, in both age groups, vaccine effectiveness against hospitalization was relatively maintained at very high levels even after 150 days.

Why Do Breakthrough Cases Occur?

Breakthrough cases are the predictable and expected result of a collision of waning immunity, new variants with immune-evading capability, high community burden of transmission, and inherent host factors as discussed below.

Booster Doses and the Wobble Stage

There is a theoretical construct vaccinologists use when thinking about delivering vaccines to a population in the context of an emerging pathogen where there is no prior immunity. The main principles of this construct include:

- Building population-level immunity very quickly. Unfortunately, we were not successful
 in doing that due to vaccine hesitancy and rejection.
- 2. Re-building immunity as it wanes with time. Boosters are required, but even they will wane with time, and far fewer people received timely boosters.
- 3. Eventually, as in the case of SAR-CoV-2 BA. 4/5, and subvariants, a new variant develops that requires re-focusing immunity to that viral variant with a variant-focused vaccine booster. This is the wobble stage that we are in right now.

Real World Effectiveness Data

Individuals who received the primary Pfizer series and then were boosted barely accumulate any measurable risks of hospitalization, while those who received only two doses suffer from more hospitalizations. This is true for both severe disease and for death.¹² If we analyze homologous versus heterologous boosting, after administering two doses of Pfizer vaccine, there was waning of vaccine effectiveness against the Delta variant but much faster and significant waning of vaccine effectiveness against variants like Omicron. When we add a Pfizer booster dose, we get a profound boost in vaccine effectiveness that begins to wane quickly. On

the other hand, when the booster dose was Moderna (heterologous boosting), effectiveness seems to be better. Thus, a "mix and match" strategy may offer some slight benefit.

Pfizer vaccine data in the elderly reveals a similar story.¹³ Measurable neutralizing ability was somewhat depressed for the Delta strain vs the Wuhan strain, but profoundly depressed for Omicron. The neutralizing ability improves with boosting, but wanes again and is more suppressed with Omicron compared to Delta and Wuhan. Moderna vaccine was also effective against infection after the second dose with waning over time, especially against Omicron. When boosted, effectiveness improves but similarly more waning of immunity was observed with Omicron than with Delta.¹⁴ There seems to be consistency across the vaccines with slightly better neutralization capability of Moderna vs Pfizer. The major point is that allowing continued viral transmission in the population will continue to result in the development of variants that will "learn" how to evade immunity by means of mutation and recombination.

Vaccine Effectiveness Against Hospitalizations

During the Omicron predominant period through January 2021, after two doses of an mRNA vaccine, effectiveness against infection fell dramatically after 5 months to the 50% range. However, with a third dose (booster dose #1) it goes back up into the 90% range, but subsequently falls into the 80% range and continues to gradually wane with time. Thus, booster doses are critical in providing the maximum amount of protection against infection, hospitalization, severe disease/death. 15, 16

Vaccine Recommendations

As a result of the above, we have seen the evolution of recommendations for vaccination. CDC now allows that the second dose can be delayed up to 8 weeks after the first dose for those who are otherwise healthy, and who are above the age of 12 and under the age of 65. The reason is that the longer the interval between doses, the better the immunogenicity and durability with reduced side effects. In fact, there is early evidence that we can decrease the already small risk of myocarditis by expanding that interval. The issue is that until two doses have been received, protection against disease is compromised. As for Johnson & Johnson vaccine, the most recent recommendation is to subsequently boost with an mRNA vaccine. In the immunocompromised host, two doses are given, with a later additional dose (3rd dose) followed by a booster dose (4th dose) two or more months after the third dose. For nonimmunocompromised persons, a newer bivalent mRNA booster is available, as is a protein subunit vaccine for use as a booster 2 or more months after the last vaccine dose. These recommendations will continue to evolve as further data become available and with the advent of new boosters and new variants that threaten health, and the CDC vaccine guidance charts should be consulted.17

Vaccine Safety

It is important to communicate that there is no such thing as "safe" with any human-made product. There is only the balance between risk and benefit and therefore the concept of

"safer". Wisdom then, resides in guiding patients in which risks to undertake for the most benefit, as there is no risk-free pathway. There are only 4 choices: COVID-19 infection, COVID-19 vaccination, passive immunity, and absolute isolation. As the J&J vaccine is no longer a preferred vaccine, below we will primarily comment on the issue of myocarditis.

Myocarditis/Myopericarditis

The predominant risk discussed in the media due to COVID vaccination is myopericarditis. There is relatively little risk of myocarditis/myopericarditis after the first dose regardless of which mRNA vaccine is administered. The second dose appears to be the issue, hence the recommendation of increasing the time interval between doses. There appears to be a greater risk with Moderna vaccine (probably due to dose), compared to Pfizer vaccine. If we look at a 7-day risk interval per million doses given, we find that this is a male-predominant side effect that happens significantly less often in females. It is more common during the pubertal period but can still happen in older individuals but with much less frequency. Examining risks versus benefits reveals that if we administer one million doses of an mRNA vaccine to men age 16 to 17 years old, we prevent about 57,000 cases of COVID-19, 500 COVID-19 related hospitalizations, and 170 COVID-19 related ICU admissions. The price we pay is 73 cases of vaccine-associated myocarditis.

If we examine the number of excess events due to vaccine exposure per million exposed, we find a significantly smaller number for myocarditis in those who received a dose or two of

mRNA vaccines compared to myocarditis in those who got COVID-19 infected. When we look at pericarditis and cardiac arrhythmias, it is almost always related to the infection.²⁰ As another example, the risk of myocarditis in patients with COVID-19 is about 16x higher versus non-infected people. The myocarditis risk is 37x higher for infected children under 16 years and 7x higher for infected people ages 16-39 compared to their uninfected peers.²¹

Another example is the risk of thrombotic thrombocytopenia syndrome (TTS) in females (30-49 age group) after receipt of the J&J vaccine. Per million doses administered in this age group, we prevent 10,000 cases of COVID-19, 900 hospitalizations, 140 ICU admissions and 20 deaths. The price we pay is 6-7 cases of GBS (Guillain-Barre Syndrome) and 8-10 cases of TTS.²² Fortunately we have other choices like an mRNA vaccine where we can eliminate the risk of TTS. As a result, the CDC now recommends that an mRNA vaccine be preferentially used over the J&J vaccine.

In summary, the new recommendation for mRNA vaccines to increase the interval between the first and second dose increases immunogenicity, decreases the risk of myocarditis, and improves antibody durability. This is tailored primarily toward healthy individuals ≥12 years old and < 65 years old, but creates some degree of tension, as there is not full protection until fully immunized.

More recently, the FDA has approved the use of a protein nanoparticle platform vaccine (Novavax). This vaccine presents the Spike protein and an adjuvant to the immune system with

robust antibody formation. Longer term data are not yet available, nor real world effectiveness data in the face of evolving viral variants. Currently, the vaccine has been submitted for use as a booster, and approval is pending.

Multiorgan-Specific Subclinical Function

There are other highly significant risks of COVID-19 infection. The data to date reveal an alarming rate and breadth of end organ long COVID complications and mental health issues.²³ In one study of 443 individuals post- SARS-CoV-2 infection, there were multiple abnormal organ specific findings that persisted 6-9 months after mild to moderate infection.²⁴ Another study demonstrated large numbers of SARS-CoV-2 RNA copies in the respiratory tract, but also in the cardiovascular system, lymph nodes, skeletal muscle, nerves, ocular tissue, optic nerve, and brain. Autopsies revealed SARS-CoV-2 protein expression in human cerebellum and Purkinje system in addition to blood vessels in the brain.²⁵

Another study looked at risks and 12 month burdens of incident post-acute COVID-19 cardiovascular outcomes. Here again regardless of age, COVID severity, and comorbidities, there was a profound excess risk burden per 1,000 people of 20 different cardiovascular outcomes with a hazard ratio (HR) in the 2-4 range for stroke, TIA, arrhythmia, myocarditis, ischemic heart disease, heart failure, and thrombotic disorders.²⁶ Finally, one study looked at mental health outcomes, particularly for those who were hospitalized with COVID-19, and

observed an elevated relative risk of a subsequent mental health diagnosis or mental health related drug prescription.²⁷ More recently, a CDC study revealed evidence of Long COVID symptoms in 20-25% of all COVID-19 cases.²⁸ To date, the nature of post-infection symptoms remains unclear, and is also associated with a variety of infections beyond COVID-19.²⁹

Glimmers of Hope and What Happens Next

The question we are most often asked is "Are we heading into the endemic phase?" There is no way to know. We believe that less severe variants may indicate movement into endemicity; however, to date, there is no evidence for this. Additionally, we do not understand the biologic, virologic, and immunologic "rules" by which viruses become endemic with one exception: high levels of immunity in the population have a "forcing" action toward endemicity in general. But, if immunity is not high enough, it can also act as a mutational pressure.

Unfortunately, due to how we failed to deal with the pandemic, SARS-CoV-2 cannot now be eradicated. The multitude of reasons for this include human behavior and continued transmission, an animal reservoir (white-tail deer, mink), waning immunity (both illness- and vaccine-induced), and importantly, continued viral mutation and recombination events.

Therefore, we can confidently predict our great, great grandchildren will be getting COVID vaccines

Anticipations

What shall we expect in the future? One scenario is that_SARS-CoV-2, under mutational and selective pressure and recombination events, further changes allowing either significantly or somewhat enhanced transmissibility and virulence. The evidence for this is the observation of the continued generation of VOCs such as BA.2.12, BA.2.12.1, BA. 2.75.2, and BA. 4/5 and their subvariants, insufficient immunogenicity of the current vaccines against variants with greater antigenic distance such as Omicron and Omicron subvariants, the continued rejection of current vaccines, and escape from monoclonal antibody, convalescent plasma, and vaccine-induced antibodies.

The second scenario is that SARS-CoV-2 mutates into a virus with significantly less transmissibility and virulence – allowing movement into the endemic phase – likely with periodic epidemic seasons. The evidence for this is currently lacking. There is no evidence for less transmissibility, and while the virulence of Omicron may be less in those previously vaccinated, that is not true for those who are unvaccinated.

Next Generation Vaccines

New COVID-19 vaccine development continues. Second generation vaccines will likely be reviewed by the FDA during 2022 and into early 2023. The first of these has already been approved - Novavax (recombinant S protein in a synthetic nanoparticle + Matrix-M). This is

likely to be followed by vaccines being developed by Medicago (recombinant S protein VLP + ASO3), and Sanofi/GSK (S protein produced in insect cells via baculovirus vector + ASO3). So-called third generation COVID vaccines may include oral and nasal spray formulations, peptide-based vaccines, and other novel formulations. Such vaccines offer the hope of inducing mucosal immunity, thereby blocking viral transmission and infection.³⁰

Conclusion:

Finally, there is a significant likelihood of a worsening pandemic surge that the world will not be capable of mitigating in the face of the currently developing ultra-transmissible Omicron subvariants. We must consider that SARS-CoV-2 is controllable with proper masking and distancing. If we add vaccines, it is eminently controllable. Yet in the third decade of the 21st century, with more scientific/medical knowledge and resources than any time in our history, we have generally proven ourselves incapable, nationally and globally, of responding in a consistently rational manner. The evidence is overwhelming. Finally, over the horizon areas of concern include very unusual SARS-CoV-2 cryptic sequences that have been identified in New York City wastewater, early evidence of reverse zoonosis, and the continued emergence of a variety of yet newer variants. We are also just starting to see the emergence and impact of the long-term population health effects of COVID-19 infection including long COVID, predisposition to chronic illnesses, neuropsychiatric and behavioral/learning disabilities and others that are yet to be recognized. The WHO concluded in 2019 that vaccine hesitancy was one of the top 10 health threats to humans – that has turned out to be true – and wisdom dictates that unless we change our course of action, we will repeatedly see new variants that will drive continuing

morbidity, mortality, and surge demands on the medical system. Such a course is untenable and immoral given the profound suffering, morbidity, mortality, and effect on economies worldwide. Have we finally learned our lesson – or is it true that humankind never learns anything from history?

References:

- Poland CM, Ratishvili T, Poland GA. Distorted Human Decision-Making as a Critical Aspect of Pandemic Planning and Preparedness. Yale J Biol Med. 2022;95:281-292.
- Woolf SH, Masters RK, Aron LY. Changes in Life Expectancy Between 2019 and 2020 in the US and 21 Peer Countries. Jama Netw Open. 2022;5.
- Poland GA, Ovsyannikova IG, Crooke SN, Kennedy RB. SARS-CoV-2 Vaccine
 Development: Current Status. Mayo Clin Proc. 2020;95:2172-2188.
- 4. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell*. 2022;185:457-466.e454.
- **5.** Felter C. How Dangerous Are New COVID-19 Strains. *Council on Foreign Relation*. 2021.
- 6. Del Rio C, Malani PN, Omer SB. Confronting the Delta Variant of SARS-CoV-2, Summer 2021. *Jama*. 2021;326:1001-1002.
- 7. Bates TA, Leier HC, Lyski ZL, et al. Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples. *Jama*. 2021;326:868-869.

- 8. Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. *Nature*. 2022;602:654-656.
- **9.** Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. *Science*. 2022;375:331-336.
- 10. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407-1416.
- 11. Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:352-358.
- Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.

 *Lancet. 2021;398:2093-2100.
- 13. Vanshylla K, Tober-Lau P, Gruell H, et al. Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults. *Lancet Infect Dis.* 2022;22:445-446.
- **14.** Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. *Nat Med.* 2022.
- **15.** Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care

- Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron

 Variant Predominance VISION Network, 10 States, August 2021-January 2022. MMWR

 Morb Mortal Wkly Rep. 2022;71:255-263.
- 16. Mehta HB, Li S, Goodwin JS. Effectiveness of COVID-19 Booster on the Risk of Hospitalization Among Medicare Beneficiaries. *Mayo Clinic Proceedings*. 2022;97:1780-1793.
- 17. Centers for Disease Control. Stay Up to Date with COVID-19 Vaccines Including Boosters. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html. Published 2022. Updated 10/14/2022. Accessed 10/20/2022, 2022..
- **18.** Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. *Bmj.* 2021;375:e068665.
- 19. Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. *Jama*. 2022;327:331-340.
- 20. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nat Med.* 2022;28:410-422.
- 21. Boehmer TK, Kompaniyets L, Lavery AM, et al. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data United States, March 2020-January 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1228-1232.
- 22. Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA

- COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory

 Committee on Immunization Practices United States, July 2021. MMWR Morb Mortal

 Wkly Rep. 2021;70:1094-1099.
- Joshee S, Vatti N, Chang C. Long-Term Effects of COVID-19. Mayo Clinic Proceedings.2022;97:579-599.
- **24.** Petersen EL, Goßling A, Adam G, et al. Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. *Eur Heart J.* 2022;43:1124-1137.
- 25. Chertow D, Stein S, Ramelli S, et al. SARS-CoV-2 infection and persistence throughout the human body and brain. 2021.
- **26.** Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nature medicine*. 2022:1-8.
- **27.** Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. *Bmj.* 2022;376:e068993.
- 28. Bull-Otterson L. Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥ 65 Years—United States, March 2020–November 2021. MMWR. Morbidity and Mortality Weekly Report. 2022;71.
- **29.** Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. *Nature Medicine*. 2022;28:911-923.
- **30.** Adashi EY, Gruppuso PA. SARS-CoV-2 Vaccines: The Mucosal Immunity Imperative. *Mayo Clinic Proceedings.* 2022;97:1771-1773.